Navigation Links
Tianyin Pharmaceutical Co., Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing on March 9
Date:3/3/2010

BEIJING, March 3 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Alternext: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced it will present at the Rodman & Renshaw Annual China Investment Conference being held March 7-9 in Beijing, China. Presentation details are noted below.

    Date:      March 9, 2010
    Time:      3:40 pm Beijing Time
    Location:  Ballroom IIi, The Regent Hotel, Beijing China
    Presenter: Dr. Guoqing Jiang, Chairman and CEO
    Joined by: Mr. Allen Tang, Assistant to the CEO

Conference participation is by invitation and registration is mandatory. For more information on the conference, or to book a one-on-one meeting, contact your Rodman & Renshaw representative or visit http://www.rodm.com .

About Rodman & Renshaw (NasdaqGM: RODM)

Rodman & Renshaw Capital Group, Inc., (NasdaqGM: RODM) offers corporate finance services focusing on various public and private equity products, which include private investment in public equity, registered direct offerings, private placements, and public offerings, as well as provides Collateralized Acquisition Pool, a product used to facilitate a targeted acquisition. The company also involves in strategic advisory services, which include identifying and/or evaluating acquisition targets or acquirers; providing valuation analyses; evaluating and proposing financial and strategic alternatives; rendering fairness opinions; advising on timing, structure, and pricing of transaction; assisting in negotiating and closing a transaction; advising on the sale process; and assisting in preparing a memorandum or other sales materials. In addition, it provides merchant banking and asset management services. Rodman & Renshaw Capital Group serves public and private biotechnology companies. The company is headquartered in New York, New York.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. Tianyin currently has 48 SFDA approved products, 41 which are manufactured and marketed. 23 of these products are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has also maintains a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 730 salespeople. The Company is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release or upcoming conference presentation are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:

     Allen Tang, Ph.D., MBA, Assistant to the CEO
     Tel:   +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:

     Mr. Matthew Hayden, HC International
     Tel:   +1-561-245-5155
     Email: matt.hayden@hcinternational.net
     Web:   http://www.hcinternational.net

SOURCE Tianyin Pharmaceutical Co., Inc.

Back to top

RELATED LINKS
http://www.tianyinpharma.com
http://www.rodm.com

'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
5. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
6. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
7. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
8. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
9. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
10. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
11. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):